2 results
Approved WMOCompleted
OX40 agonists have been shown to increase antitumor immunity and improve tumor-free survival in non-clinical models and OX40 agonist monoclonal antibodies (mAbs) are currently being evaluated in Phase I clinical trials. GSK3174998 is a humanized…
Approved WMORecruiting
This entry-into-human (EIH) Phase Ia/Ib study aims to establish the safety,pharmacokinetics, immunogenicity, and pharmacodynamics of RO7284755 (alone or incombination with atezolizumab) and to evaluate its anti-tumor activity.